ABSTRACT
Investigations of the association of patient outcome with a few candidate single nucleotide polymorphisms (SNPs) or much larger numbers of SNPs have been undertaken in various therapeutic studies in oncology (e.g., Durie et al. 2009, Song et al. 2010). Since the genomic material often consists of germline DNA, not tumor DNA, the primary associations to therapeutic efficacy are typically not expected to be as strong as those seen for tumor gene expression. However, even with non-tumor 592DNA, there could potentially be some strong correlations with disease symptoms at diagnosis, measures of drug metabolism and patient adverse events due to treatment.
